X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
index medicus (52) 52
melanoma (51) 51
oncology (41) 41
cancer (36) 36
cell line, tumor (34) 34
cell biology (32) 32
mutation (28) 28
melanoma - genetics (24) 24
melanoma - drug therapy (21) 21
melanoma - pathology (21) 21
melanoma - metabolism (20) 20
dermatology (19) 19
metastatic melanoma (18) 18
apoptosis (17) 17
proto-oncogene proteins b-raf - antagonists & inhibitors (17) 17
immunotherapy (15) 15
proto-oncogene proteins b-raf - genetics (15) 15
acquired-resistance (14) 14
female (14) 14
proteins (14) 14
tumors (14) 14
animals (13) 13
research (13) 13
resistance (13) 13
analysis (12) 12
cell proliferation (12) 12
male (12) 12
middle aged (12) 12
patients (12) 12
signal transduction (12) 12
adult (11) 11
care and treatment (11) 11
drug resistance, neoplasm - genetics (11) 11
mutations (11) 11
p53 (11) 11
tumor suppressor protein p53 - metabolism (11) 11
aged (10) 10
biochemistry (10) 10
cyclin-dependent kinase inhibitor p16 - metabolism (10) 10
melanocytes - metabolism (10) 10
neoplasms (10) 10
proto-oncogene proteins b-raf - metabolism (10) 10
skin neoplasms - pathology (10) 10
survival (10) 10
vemurafenib (10) 10
biochemistry & molecular biology (9) 9
cell cycle (9) 9
dabrafenib (9) 9
expression (9) 9
kinases (9) 9
mice (9) 9
molecular biology (9) 9
p16 (9) 9
protein kinase inhibitors - pharmacology (9) 9
senescence (9) 9
drug resistance, neoplasm (8) 8
gene (8) 8
gene expression (8) 8
medical research (8) 8
p14 (8) 8
protein (8) 8
research article (8) 8
skin neoplasms - metabolism (8) 8
solid tumors (8) 8
tumor suppressor protein p14arf - metabolism (8) 8
article (7) 7
cyclin-dependent kinase inhibitor p16 - genetics (7) 7
in-vivo (7) 7
inhibition (7) 7
inhibitors (7) 7
malignant-melanoma (7) 7
mek inhibitors (7) 7
metastases (7) 7
metastasis (7) 7
open-label (7) 7
transcription factors - metabolism (7) 7
tumor suppressor protein p14arf - genetics (7) 7
amino acid sequence (6) 6
amplification (6) 6
biomarkers (6) 6
braf (6) 6
cdk4 (6) 6
disease (6) 6
familial melanoma (6) 6
genetic aspects (6) 6
genetics & heredity (6) 6
map kinase (6) 6
map kinase signaling system - drug effects (6) 6
molecular sequence data (6) 6
neoplasm metastasis (6) 6
neoplasms. tumors. oncology. including cancer and carcinogens (6) 6
signaling (6) 6
skin neoplasms - genetics (6) 6
therapy (6) 6
tumor suppressor protein p53 - genetics (6) 6
1-phosphatidylinositol 3-kinase (5) 5
antineoplastic agents - therapeutic use (5) 5
binding (5) 5
biology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue S11, pp. 2118 - 2129
The identification of driver mutations in melanoma has changed the field of cancer treatment. BRAF and NRAS mutations are predominant in melanoma and lead to... 
targeted therapy | phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) pathway | BRAF inhibitors | mitogen‐activated protein kinase kinase (MEK) inhibitors | immunotherapy | melanoma | mitogen‐activated protein kinase (MAPK) pathway | phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway | mitogen-activated protein kinase kinase (MEK) inhibitors | mitogen-activated protein kinase (MAPK) pathway | MUTANT MELANOMA | PD-L1 EXPRESSION | ACQUIRED-RESISTANCE | OPEN-LABEL | MEK INHIBITORS | METASTATIC MELANOMA | PHASE-II TRIAL | ONCOLOGY | CUTANEOUS MELANOMA | BRAF INHIBITOR RESISTANCE | RAF INHIBITORS | Niacinamide - analogs & derivatives | Immunotherapy - methods | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | MAP Kinase Kinase 1 - genetics | Melanoma - genetics | Benzimidazoles - therapeutic use | MAP Kinase Kinase 1 - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Signal Transduction | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Phosphatidylinositol 3-Kinases - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Melanoma - drug therapy | Skin Neoplasms - genetics | Indoles - therapeutic use | CTLA-4 Antigen - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Therapy | Melanoma | MAP kinase | AKT protein | Drug resistance | Kinases | Cancer therapies | Patients | 1-Phosphatidylinositol 3-kinase | Metastases | Signal transduction | Inhibitors | Pathways | New combinations | Effectors | Mutation | Cancer
Journal Article
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2016, Volume 29, Issue 3, pp. 260 - 261
Journal Article
Nature Communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 5694
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 18, pp. 2792 - 2799
Abstract Background Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In... 
Hematology, Oncology and Palliative Medicine | Resistance | Vemurafenib | NRAS | Splice | Acquired | Dabrafenib | BRAF | MEK1 | MAPK | Meta-analysis | SURVIVAL | RAF INHIBITION | METASTATIC MELANOMA | THERAPY | ONCOLOGY | PATHWAY | COBIMETINIB | B-RAF | MUTATIONS | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - therapeutic use | Skin Neoplasms - enzymology | Time Factors | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Biomarkers, Tumor - metabolism | Female | Biomarkers, Tumor - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Skin Neoplasms - pathology | Genetic Predisposition to Disease | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Melanoma - pathology | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Phenotype | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Mutation | Australia | Melanoma - mortality | splice | vemurafenib | meta-analysis | resistance | amplification | spectrum | MEK2 | dabrafenib | acquired
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 2/2019, Volume 20, Issue 1, pp. 1 - 12
Genetic material derived from tumours is constantly shed into the circulation of cancer patients both in the form of circulating free nucleic acids and within... 
Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | BLOOD COLLECTION TUBES | METASTATIC MELANOMA | DROPLET DIGITAL PCR | CANCER-PATIENTS | CELL-FREE-DNA | ACQUIRED-RESISTANCE | GENOMIC ALTERATIONS | LIQUID BIOPSIES | MALIGNANT-MELANOMA | TUMOR DNA | DERMATOLOGY
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 07/2014, Volume 124, Issue 7, pp. 2877 - 2890
About half of all melanomas harbor a mutation that results in a constitutively active BRAF kinase mutant (BRAF(V6005E/K)) that can be selectively inhibited by... 
BREAST-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | METASTATIC MELANOMA | SIGNALING PATHWAY | COLORECTAL-CANCER | CUTANEOUS MELANOMA | THERAPEUTIC TARGET | ACQUIRED-RESISTANCE | MALIGNANT-MELANOMA | WNT/BETA-CATENIN PATHWAY | MEDIATES RESISTANCE | Frizzled Receptors - antagonists & inhibitors | Humans | Cell Survival - genetics | Wnt-5a Protein | Wnt Proteins - metabolism | Wnt Proteins - genetics | RNA Interference | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Frizzled Receptors - metabolism | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | beta Catenin - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Up-Regulation - drug effects | Drug Resistance, Neoplasm - genetics | Frizzled Receptors - genetics | Wnt Signaling Pathway - drug effects | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Mutation | Wnt Proteins - antagonists & inhibitors | Care and treatment | Oncology, Experimental | Melanoma | Genetic aspects | Research | Drug resistance | Cancer | Proteins | Studies | Medical research | Kinases | Gene expression | Experiments | Drug dosages | Patients | Tumors
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 765 - 765
Journal Article
Pigment cell & melanoma research, ISSN 1755-1471, 09/2019
Inhibitors targeting the mitogen-activated protein kinase (MAPK) pathway and immune checkpoint molecules have dramatically improved the survival of patients... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2017, Volume 23, Issue 12, pp. 2921 - 2923
Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental... 
Immune checkpoint | PD-1 protein | Tumors | Metastases | Cancer
Journal Article